All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL hub

ALL hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.

Disease AreasTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2023-11-01T10:26:07.000Z

ACR Convergence 2023: Top abstracts in psoriasis and psoriatic arthritis

By Ella Dixon
Nov 1, 2023
Share:

To help navigate the exciting content being presented at American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

Psoriasis

2255

Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial

1920

A Phase Ib/II randomized, double-blind, placebo-controlled study of novel anti-IL-17A monoclonal antibody JS005 in patients with moderate to severe psoriasis

1418

Efficacy of the oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active PsA: Results from a phase 2 trial

0261

Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results

0443

The potential of an oral TNFα inhibitor with TNFR1 specificity: Results of a phase 1b proof-of-mechanism trial in psoriasis

 

Psoriatic arthritis

1433

Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA) domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies

1422

Long-term safety of risankizumab in patients with psoriatic disease: integrated analysis of psoriasis and psoriatic arthritis clinical trial data

L12

Efficacy and safety outcomes of TAK-279, a selective oral tyrosine kinase 2 (TYK2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis

0485

Sex and treatment-associated outcomes in patients with active psoriatic arthritis treated with deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial

0776

Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: 16- and 52-week results from a randomized, double-blind, phase 3 study

 

ACR Convergence 2023 Abstracts

To download this document, click below.

Download here

More about...
ACR 2023PsoriasisPsoriatic arthritis

Your opinion matters

HCPs, what is your preferred format for educational content on the PsOPsA Hub?
6 votes - 80 days left ...

Related articles

Add bookmark

Small-molecule systemic oral therapies for psoriasis and PsA

Here, we will focus on small-molecule systemic oral therapies for use in psoriasis, which can be useful for patients who do not yield a response to other treatments, or who have a...

Mar 28, 2024
Add bookmark

Small-molecule systemic oral therapies for psoriasis and PsA

Here, we will focus on small-molecule systemic oral therapies for use in psoriasis, which can be useful for patients who do not yield a...

Mar 28, 2024
Add bookmark

EADV 2023: Top abstracts in psoriasis and psoriatic arthritis

To help navigate the exciting content being presented at the EADV 2023 Congress, we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic...

Oct 10, 2023
Add bookmark

EADV 2023: Top abstracts in psoriasis and psoriatic arthritis

To help navigate the exciting content being presented at the EADV 2023 Congress, we have provided recommendations for the top abstracts to...

Oct 10, 2023

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox